Compare Johnson & Johnson (JNJ) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs ProShares Ultra QQQ ETF — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while ProShares Ultra QQQ ETF trades at $98.43 (market cap $15.38B). The key difference: Johnson & Johnson is far larger — about 40.2× ProShares Ultra QQQ ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| JNJ | QLD | |
|---|---|---|
Market Cap | $618.09B | $15.38B |
Volume | 6,050,983 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $278.43 | $100.77 |
52-Week Low | $186.00 | $57.16 |
Typical Hold Time | 129 Days | 36 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
QLD (ProShares Ultra QQQ ETF) trades at $97.56, down 2.66% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, positioned as a less volatile alternative to triple-leveraged products. Recent institutional buying and media coverage highlight investor interest in leveraged tech exposure amid market uncertainty.
The outlook for QLD hinges on Nasdaq-100 performance, with technical support at $96 and resistance at $100. While leveraged ETFs offer amplified returns, they carry elevated risk during market downturns. Current sentiment is cautiously optimistic, but investors should be aware of decay effects and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
